×

Biotech and Pharmaceuticals Pharmaceuticals

  • Amgen osteoporosis drug imperiled by safety concerns

    CNBC's Meg Tirrell reports on Amgen stocks falling today after a drug risk.

  • The drug, romosozumab, which would be sold under the brand name Evenity if approved, is awaiting an approval decision by the Food and Drug Administration. But the new safety data, which cropped up in an otherwise successful trial, will have to be taken into consideration, delaying any FDA decision and leaving the product's future uncertain. The news is a blow for...

  • The drug, romosozumab, which would be sold under the brand name Evenity if approved, is awaiting an approval decision by the Food and Drug Administration. But the new safety data, which cropped up in an otherwise successful trial, will have to be taken into consideration, delaying any FDA decision and leaving the product's future uncertain. The news is a blow for...

  • SEOUL, May 19- A unit of healthcare conglomerate Johnson& Johnson filed a lawsuit to block a copy of its rheumatoid arthritis drug Remicade made by South Korea's Samsung Bioepis Co Ltd from being sold in the United States. Janssen's lawsuit comes about a month after Samsung, an unlisted subsidiary of contract drug maker Samsung BioLogics Co Ltd, said it got U.S....

  • Mallinckrodt shares hit a session low of $39.60 after the comments and were last down 3.5 percent. The U.S. Justice Department has been investigating Mallinckrodt along with other drug companies like Gilead, Valeant and Celgene for drug pricing practices. Earlier this year, Mallinckrodt agreed to pay $100 million to settle a lawsuit alleging that a company it...

  • SACRAMENTO, Calif.— The California Senate passed a bill Thursday that would ban drug companies from giving gifts to doctors. The Senate voted 23-13 to send the bill to the Assembly. Drug companies spend more than $1.4 billion a year on gifts to California doctors, said McGuire, a Democrat who represents a district west of Sacramento.

  • *U.S. shares rise 3.4 pct, UK stock up 1.7 pct. May 18- Successful late-stage data on Shire Plc's, long-acting preventative treatment for hereditary angioedema brings the Dublin- based drugmaker one step closer to U.S. approval, it said on Thursday. It affects about one in 50,000 people, according to the U.S. National Institutes of Health.

  • *Action targets 300 medicines India categorizes as essential. MUMBAI, May 18- India's drug pricing regulator has demanded explanations from 65 domestic and global drugmakers for selling new forms of essential diabetes and antibiotic drugs without its approval. The action targets a group of more than 300 medicines that India defines as essential, whose...

  • What to watch at ASCO cancer conference

    CNBC's Meg Tirrell reports on the major names making waves in cancer research ahead of the American Society of Clinical Oncology conference.

  • Here's what the latest data on cancer research means for biotech stocks

    CNBC's Meg Tirrell reports on the drug stocks reacting to the data dump. The "Fast Money" traders weigh in.

  • Jeff Bezos

    Robert Willoughby, Credit Suisse, weighs in on a report from CNBC that Amazon will explore entry into the pharmaceutical industry.

  • Cancer data deluge set to move stocks

    CNBC's Meg Tirrell reports on the biotech stocks to watch, including a new player Incyte, as well as Johnson and Johnson's analyst day and Amazon's pharmaceutical break in. "Fast Money Halftime Report" traders and Kevin O'Leary weigh in.

  • J&J CEO: We have to pay attention to out-of-pocket drug costs

    Alex Gorsky, Johnson & Johnson CEO, speaks with CNBC's Meg Tirrell about the company's pharmaceutical business, drug pricing and health-care reform.

  • May 16- Danish drugmaker Novo Nordisk said on Tuesday the chief executive of Canadian biotech company Novelion Therapeutics had left its board with immediate effect due to "a potential conflict of interest." The departure of Mary Szela follows her firm's decision to work on non-alcoholic steatohepatitis, or fatty liver, a Novo company spokeswoman said.

  • Moderna Therapeutics recently revealed that it's working on vaccines for the flu and Zika virus and a therapy for heart failure.

  • Billionaire investor Carl Icahn sold out of the pharmaceutical giant entirely, while Farallon Capital Management LLC, David Tepper's Appaloosa LP and Seth Klarman's Baupost Group LLC were among those trimming their stakes by as much as 32 percent, according to regulatory filings. Paulson& Co Inc and Leon Cooperman's Omega Advisors Inc also pulled back on the...

  • *Sees deal adding 30 cents to adjusted EPS in first year. May 15- Thermo Fisher Scientific Inc said on Monday it would buy Patheon NV, a Dutch manufacturer of drugs for clinical trials, for $5.2 billion as it seeks to complement its offerings in production and services for the biopharma industry. Thermo will also assume $2 billion in net debt, putting the cost of the...

  • Watch short-seller Andrew Left battle the CEO of his latest short position

    Andrew Left, short seller, and Kevin Conroy, Exact Sciences CEO debate a study about Exact Sciences colonoscopy tests.

  • Short seller's bear debate on Exact Sciences

    Andrew Left, activist short seller, discusses the bear debate on Exact Sciences with Kevin Conroy, Exact Sciences CEO.

  • CARLSBAD, Calif. _ Natural Alternatives International Inc. on Monday reported fiscal third-quarter earnings of $745,000. Natural Alternatives shares have declined 14 percent since the beginning of the year. Keywords: Natural Alternatives, Earnings Report.